What are you looking for?

Need help finding what you are looking for? Contact Us

Compare

Free Samples

Home Market Research Reports Pharmaceutical

PUBLISHER: The Business Research Company | PRODUCT CODE: 1415611

PUBLISHER: The Business Research Company | PRODUCT CODE: 1415611

Progressive Multifocal Leukoencephalopathy Treatment Global Market Report 2024

PUBLISHED: January 24, 2024

PAGES: 175 Pages

DELIVERY TIME: 2-10 business days

ADD TO COMPARE

SELECT AN OPTION

Description

“Progressive Multifocal Leukoencephalopathy Treatment Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on progressive multifocal leukoencephalopathy treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for progressive multifocal leukoencephalopathy treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The progressive multifocal leukoencephalopathy treatment market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Treatment: Anti-retroviral Therapy; Antiviral Or Anti-John Cunningham Virus (JCV); Other Symptomatic
2) By Indication: HIV Or AIDS; Organ Transplantation; Multiple Sclerosis; Hematologic Malignancies
3) By Route of Administration: Oral; Parenteral; Other Routes Of Administration
4) By End-Users: Hospitals; Homecare; Specialty Centers; Other End-Users
Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Roche Holding AG; Merck & Co. Inc.; AbbVie Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Progressive multifocal leukoencephalopathy is a rare and severe viral brain infection that primarily afflicts individuals with weakened immune systems. Treatment aims to manage symptoms, slow the disease's progression, and prevent complications. Unfortunately, there is currently no known cure for PML, and the damage caused by the virus cannot be reversed.

The main treatment approaches for progressive multifocal leukoencephalopathy include anti-retroviral therapy, antiviral or anti-John Cunningham virus (JCV) medications, and other interventions. Anti-retroviral therapy involves a combination of drugs used to manage infections caused by retroviruses, especially the human immunodeficiency virus (HIV). These therapies are employed in conditions such as HIV/AIDS, organ transplantation, multiple sclerosis, and hematologic malignancies. They can be administered through various methods, including oral and parenteral routes, and are utilized by a range of healthcare facilities, including hospitals, homecare services, specialty centers, and more.

The progressive multifocal leukoencephalopathy market research report is one of a series of new reports from The Business Research Company that provides progressive multifocal leukoencephalopathy market statistics, including progressive multifocal leukoencephalopathy industry global market size, regional shares, competitors with a progressive multifocal leukoencephalopathy market share, detailed progressive multifocal leukoencephalopathy market segments, market trends and opportunities and any further data you may need to thrive in the progressive multifocal leukoencephalopathy industry. This progressive multifocal leukoencephalopathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The progressive multifocal leukoencephalopathy treatment market size has grown rapidly in recent years. It will grow from $1.31 billion in 2023 to $1.46 billion in 2024 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to prevalence of underlying conditions, rise in immunosuppressed patients, patient advocacy and awareness, rise of hiv/aids epidemic.

The progressive multifocal leukoencephalopathy treatment market size is expected to see rapid growth in the next few years. It will grow to $2.15 billion in 2028 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to increasing digital health and telemedicine, growing adoption of targeted therapy, improved diagnostic tools, growing awareness of progressive multifocal leukoencephalopathy (pml). Major trends in the forecast period include technological advancements in progressive multifocal leukoencephalopathy (pml) treatment, research and clinical trials, early diagnosis and screening, development of new drug therapies.

The expected increase in the prevalence of human immunodeficiency virus (HIV) infection is anticipated to be a driving force behind the expansion of the progressive multifocal leukoencephalopathy (PML) market. HIV, a retrovirus, targets the immune system, specifically CD4 cells (also known as T cells), which play a crucial role in the body's defense against infections. PML is most commonly observed in patients with HIV due to their compromised immune status, often characterized by a low CD4 cell count (below 200/L), which is the primary factor contributing to PML cases worldwide. When there is a severe immune deficiency related to HIV, the latent John Cunningham virus (JCV) archetype strain in the brain can become active, leading to the development of brain white matter lesions and PML. For instance, as of December 2022, data from the Joint United Nations Programme on HIV and AIDS (UNAIDS), a Switzerland-based United Nations initiative focused on AIDS, indicates that 630,000 (480,000-880,000) people succumbed to AIDS-related illnesses, and there were 39.0 million (33.1 million-45.7 million) individuals living with HIV worldwide. In 2022, an additional 1.3 million (1 million-1.7 million) people were newly diagnosed with HIV. Consequently, the increasing prevalence of HIV infection is a key factor propelling the growth of the progressive multifocal leukoencephalopathy market.

The anticipated growth of the progressive multifocal leukoencephalopathy treatment market is expected to be propelled by the increasing research and development (R&D) activities. Rising R&D activities involve the growing efforts and investments dedicated to scientific investigation, experimentation, and innovation across various fields. In the context of progressive multifocal leukoencephalopathy (PML), such research and development endeavors are of paramount importance, as they contribute to the development of improved therapies, earlier diagnosis methods, and enhanced disease management. For example, in July 2023, the Office for National Statistics, a UK-based government department, reported that the expenditure on research and development (R&D) conducted in the UK reached $80.9 billion (£66.2 billion) in 2021, reflecting an increase of $5.25 billion (£4.3 billion) since 2020. Consequently, the upsurge in research and development activities is a driving force behind the progressive multifocal leukoencephalopathy treatment market's growth.

High treatment costs in the progressive multifocal leukoencephalopathy market pose a challenge and could potentially impede market growth in the forecast period. Patients with progressive multifocal leukoencephalopathy often incur significant expenses for supportive care, hospitalization, and specialized diagnostic tests. For example, in the year leading up to February 2022, hospitalization costs in the United States increased by 2.1%, as reported by the American Hospital Association. As a result, the substantial treatment expenses are a limiting factor for the progressive multifocal leukoencephalopathy market's expansion.

Leading companies in the progressive multifocal leukoencephalopathy (PML) treatment market are increasingly dedicating their efforts to innovating their products to offer reliable solutions to their customers and to bolster their market standing. As an example, in October 2022, Cellevolve Bio, a clinical company based in the United States, obtained clearance from the United States Food and Drug Administration (FDA) for an investigational new drug (IND) application and secured orphan drug designation for CE-VST01-JC. This drug is developed to address progressive multifocal leukoencephalopathy and will undergo assessment in a global, multi-center, randomized, double-blind, placebo-controlled Phase 2 trial named ASCEND-JC. The primary objective of this trial is to compare the efficacy of CE-VST01-JC with a placebo, aiming to determine whether CE-VST01-JC can mitigate or prevent neurological progression in patients with PML. CE-VST01-JC is a T-cell therapy precisely targeting the JC virus, the causal agent of PML. This represents a significant milestone for both the PML community and Cellevolve, as ASCEND-JC stands as the largest-ever cell treatment study in the realm of PML research.

In December 2021, Cellevolve Bio, a clinical company headquartered in the United States, entered into a collaboration with the QIMR Berghofer Medical Research Institute to expedite the development of an innovative bioengineered T-cell therapy for cellular immunotherapies aimed at addressing John Cunningham's (JC) progressive multifocal leukoencephalopathy. This devastating disease, known as progressive multifocal leukoencephalopathy (PML), is caused by the JC virus and affects the white matter of the brain. Within the framework of this agreement, QIMR Berghofer has entered into a licensing, research, and manufacturing partnership with Cellevolve Bio for a novel cellular immunotherapy. The QIMR Berghofer Medical Research Institute is based in Australia and specializes in T-cell and allogeneic cell therapies.

Major players in the progressive multifocal leukoencephalopathy treatment market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol Myers Squibb Company, Sanofi S.A., Takeda Pharmaceutical Company Limited, Acorda Therapeutics, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Jazz Pharmaceuticals plc, Ipsen Pharma, Apotex Inc., Alkermes plc, Alnylam Pharmaceuticals Inc., Genentech Inc., Karyopharm Therapeutics Inc., ARIAD Pharmaceuticals Inc., Spectrum Pharmaceuticals, Neurimmune AG, NeoImmuneTech, Inhibikase Therapeutics Inc.

North America was the largest region in the progressive multifocal leukoencephalopathy treatment market in 2023. The regions covered in the progressive multifocal leukoencephalopathy treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the progressive multifocal leukoencephalopathy treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The progressive multifocal leukoencephalopathy treatment market consists of revenues earned by entities by providing plasmapheresis, immune reconstitution therapy, physical therapy, supportive care, and consultation. The market value includes the value of related goods sold by the service provider or included within the service offering. The progressive multifocal leukoencephalopathy treatment market also includes sales of cidofovir, Brin cidofovir, and mefloquine. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r12210

1. Executive Summary

2. Progressive Multifocal Leukoencephalopathy Treatment Market Characteristics

3. Progressive Multifocal Leukoencephalopathy Treatment Market Trends And Strategies

4. Progressive Multifocal Leukoencephalopathy Treatment Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Progressive Multifocal Leukoencephalopathy Treatment Market Size and Growth

5.1. Global Progressive Multifocal Leukoencephalopathy Treatment Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Progressive Multifocal Leukoencephalopathy Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Progressive Multifocal Leukoencephalopathy Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Progressive Multifocal Leukoencephalopathy Treatment Market Segmentation

6.1. Global Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Anti-retroviral Therapy
Antiviral Or Anti-John Cunningham Virus (JCV)
Other Symptomatic
6.2. Global Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
HIV Or AIDS
Organ Transplantation
Multiple Sclerosis
Hematologic Malignancies
6.3. Global Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Oral
Parenteral
Other Routes Of Administration
6.4. Global Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Homecare
Specialty Centers
Other End-Users

7. Progressive Multifocal Leukoencephalopathy Treatment Market Regional And Country Analysis

7.1. Global Progressive Multifocal Leukoencephalopathy Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Progressive Multifocal Leukoencephalopathy Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Progressive Multifocal Leukoencephalopathy Treatment Market

8.1. Asia-Pacific Progressive Multifocal Leukoencephalopathy Treatment Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Progressive Multifocal Leukoencephalopathy Treatment Market

9.1. China Progressive Multifocal Leukoencephalopathy Treatment Market Overview
9.2. China Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Progressive Multifocal Leukoencephalopathy Treatment Market

10.1. India Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Progressive Multifocal Leukoencephalopathy Treatment Market

11.1. Japan Progressive Multifocal Leukoencephalopathy Treatment Market Overview
11.2. Japan Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Progressive Multifocal Leukoencephalopathy Treatment Market

12.1. Australia Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Progressive Multifocal Leukoencephalopathy Treatment Market

13.1. Indonesia Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Progressive Multifocal Leukoencephalopathy Treatment Market

14.1. South Korea Progressive Multifocal Leukoencephalopathy Treatment Market Overview
14.2. South Korea Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Progressive Multifocal Leukoencephalopathy Treatment Market

15.1. Western Europe Progressive Multifocal Leukoencephalopathy Treatment Market Overview
15.2. Western Europe Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Progressive Multifocal Leukoencephalopathy Treatment Market

16.1. UK Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Progressive Multifocal Leukoencephalopathy Treatment Market

17.1. Germany Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Progressive Multifocal Leukoencephalopathy Treatment Market

18.1. France Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Progressive Multifocal Leukoencephalopathy Treatment Market

19.1. Italy Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Progressive Multifocal Leukoencephalopathy Treatment Market

20.1. Spain Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Progressive Multifocal Leukoencephalopathy Treatment Market

21.1. Eastern Europe Progressive Multifocal Leukoencephalopathy Treatment Market Overview
21.2. Eastern Europe Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Progressive Multifocal Leukoencephalopathy Treatment Market

22.1. Russia Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Progressive Multifocal Leukoencephalopathy Treatment Market

23.1. North America Progressive Multifocal Leukoencephalopathy Treatment Market Overview
23.2. North America Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Progressive Multifocal Leukoencephalopathy Treatment Market

24.1. USA Progressive Multifocal Leukoencephalopathy Treatment Market Overview
24.2. USA Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Progressive Multifocal Leukoencephalopathy Treatment Market

25.1. Canada Progressive Multifocal Leukoencephalopathy Treatment Market Overview
25.2. Canada Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Progressive Multifocal Leukoencephalopathy Treatment Market

26.1. South America Progressive Multifocal Leukoencephalopathy Treatment Market Overview
26.2. South America Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Progressive Multifocal Leukoencephalopathy Treatment Market

27.1. Brazil Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Progressive Multifocal Leukoencephalopathy Treatment Market

28.1. Middle East Progressive Multifocal Leukoencephalopathy Treatment Market Overview
28.2. Middle East Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Progressive Multifocal Leukoencephalopathy Treatment Market

29.1. Africa Progressive Multifocal Leukoencephalopathy Treatment Market Overview
29.2. Africa Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Progressive Multifocal Leukoencephalopathy Treatment Market, Segmentation End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Progressive Multifocal Leukoencephalopathy Treatment Market Competitive Landscape And Company Profiles

30.1. Progressive Multifocal Leukoencephalopathy Treatment Market Competitive Landscape
30.2. Progressive Multifocal Leukoencephalopathy Treatment Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Johnson & Johnson
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Roche Holding AG
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Merck & Co. Inc.
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. AbbVie Inc.
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Progressive Multifocal Leukoencephalopathy Treatment Market Other Major And Innovative Companies

31.1. Novartis AG
31.2. Bristol Myers Squibb Company
31.3. Sanofi S.A.
31.4. Takeda Pharmaceutical Company Limited
31.5. Acorda Therapeutics
31.6. Eli Lilly and Company
31.7. Gilead Sciences Inc.
31.8. Amgen Inc.
31.9. Viatris Inc.
31.10. Teva Pharmaceutical Industries Ltd.
31.11. Biogen Inc.
31.12. Eisai Co. Ltd.
31.13. Otsuka Pharmaceutical Co. Ltd.
31.14. Jazz Pharmaceuticals plc
31.15. Ipsen Pharma

32. Global Progressive Multifocal Leukoencephalopathy Treatment Market Competitive Benchmarking

33. Global Progressive Multifocal Leukoencephalopathy Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Progressive Multifocal Leukoencephalopathy Treatment Market

35. Progressive Multifocal Leukoencephalopathy Treatment Market Future Outlook and Potential Analysis

35.1 Progressive Multifocal Leukoencephalopathy Treatment Market In 2028 - Countries Offering Most New Opportunities
35.2 Progressive Multifocal Leukoencephalopathy Treatment Market In 2028 - Segments Offering Most New Opportunities
35.3 Progressive Multifocal Leukoencephalopathy Treatment Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ